Given RUNX2’s involvement in transcriptional networks associated with metabolism and tumor progression, it may serve as an upstream regulator of MAEA or its related pathways, thereby modulating chemotherapy resistance in tumors such as osteosarcoma. This evidence concerns the gene MAEA and neoplasm.